Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.41 |
| ▸ | KHK | P50053 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026858 | 0.92 | HRH3 (0.47) | GLSHRH3FFAR4PDE4B | |
| SCHEMBL28378104 | 0.88 | GLS (0.40) | GLSHRH3FFAR4KHK | |
| Trifluoroacetic Acid SCHEMBL1027148 | 0.84 | HRH3 (0.42) | GLSHRH3FFAR4PDE4B | |
| SCHEMBL1025896 | 0.78 | HSD17B10 (0.50) | HRH3FFAR4 | |
| SCHEMBL21135461 | 0.74 | POLB (0.42) | GLSHRH3KHK | |
| SCHEMBL30455873 | 0.72 | HRH3 (0.34) | GLSHRH3 | |
| SCHEMBL4335035 | 0.71 | HRH3 (0.59) | GLSHRH3 | |
| SCHEMBL1074321 | 0.71 | HRH3 (0.43) | GLSHRH3FFAR4 | |
| SCHEMBL29973419 | 0.70 | HRH3 (0.39) | GLSHRH3 | |
| SCHEMBL12209978 | 0.70 | NOTUM (0.58) | HRH3FFAR4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | GLS 751/4885HRH3 1871/4885FFAR4 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.